arrow
E

Elaine Shum

new york university nyu langone perlmutter cancer center
H指数:19
被引数:1,578

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025

肺癌护理中的当前挑战与新兴治疗策略:Bridging the Gaps 2025的见解

Cancer
IF5.1
2026-09-290
PRE
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

晚期实体瘤患者AXL特异性抗体药物偶联物Enapotamab Vedotin的I/II期研究

2025-11-010
OA
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024

肺癌管理临床策略:2024年弥合差距肺癌共识会议的建议

Cancer
IF5.1
2025-08-260
PRE
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945

深度突变扫描揭示了赋予对第四代EGFR酪氨酸激酶抑制剂BLU-945耐药性的EGFR突变。

2025-08-200
OAAI
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Datopotamab Deruxtecan在EGFR突变非小细胞肺癌患者中的合并分析

2025-06-120
OAAI
Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05

达波替安德鲁克坦(Dato-DXd)在既往治疗过的EGFR突变型晚期非小细胞肺癌(NSCLC)患者(pts)中的有效性与安全性:TROPION-Lung01和TROPION-Lung05的合并分析

2024-12-012
PRE
Lung cancer research and treatment: global perspectives and strategic calls to action

肺癌研究与治疗: 全球视角与战略行动呼吁

2024-12-010
PRE
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

前20名EGFR NSCLC临床和转化科学论文,塑造了NSCLC中激活EGFR突变发现的20年。主编专家小组共识调查。

2024-06-010
OAAI
Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial
2023-12-010
PRE
IMPACTS ON MANAGEMENT OF HIGH-RISK LUNG NODULES AND PATIENT OUTCOMES AFTER VIRTUAL REVIEW BY A MULTIDISCIPLINARY LUNG NODULE REVIEW BOARD
CHEST
IF8.6
2023-10-010
PRE
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
2022-09-089
OAAI